mātakina is pleased to announce that it has attained FDA clearance to start marketing its revolutionary Volpara breast imaging software into the $1Bn, US breast imaging market.
The Volpara product automatically computes breast density from the standard breast x-rays taken when a woman attends breast screening. Breast density has been linked to the sensitivity of x-rays for the detection of breast cancer, the risk of a woman developing breast cancer, the risk of recurrence of breast cancer after surgery, and the use of certain drugs.
Matakina’s CEO, Dr Ralph Highnam, says
“Volpara will improve the radiologist’s understanding of breast composition and will help them select the right imaging modalities and procedures to ensure that each and every woman is screened in the most appropriate manner. We now have trials underway of Volpara right across the globe and it’s great that the FDA has now recognized Volpara as being safe and effective, so that we can begin helping radiologists help women.”